STERIS Q2 FY2026 revenue up 10% to $1.5B; adjusted EPS $2.47; raises FY outlook

STERIS plc

2026-Q2 EPS reported $3.74 revenue$2,851,400,000

Q2 revenue $1.5B (+10% YoY); constant currency organic revenue +9%.
As-reported EPS $1.94; adjusted EPS $2.47 versus $2.14 last year.
Healthcare revenue +9%, AST +10%, Life Sciences +13% (all as reported).
FY2026 adjusted EPS guidance raised to $10.15-$10.30 (prior $9.90-$10.15).
Free cash flow outlook increased to ~$850M; tariff impact unchanged at ~$45M pretax.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.